What Is the DTwP Vaccine and What Does It Prevent?

The DTwP vaccine is a combination shot that protects against three serious bacterial diseases: diphtheria, tetanus, and pertussis (whooping cough). The “wP” stands for “whole-cell pertussis,” meaning it contains killed but intact Bordetella pertussis bacteria as one of its active components, along with inactivated toxins (toxoids) for diphtheria and tetanus. First developed in the 1930s and put into routine use in the 1940s, DTwP dramatically reduced all three diseases and remains one of the most widely administered childhood vaccines in the world, particularly in low- and middle-income countries.

The Three Diseases DTwP Targets

Each component of the vaccine addresses a distinct and potentially fatal infection. Understanding what these diseases actually do to the body helps explain why vaccination against them became a public health priority in the first place.

Diphtheria is caused by the bacterium Corynebacterium diphtheriae, which produces a potent toxin that damages the heart, kidneys, and nervous system. The hallmark of respiratory diphtheria is a thick grayish membrane that forms in the throat, sometimes blocking the airway entirely. In a recent study from Nigeria, where a diphtheria outbreak occurred among largely unvaccinated children, common symptoms included fever, sore throat, painful swallowing, and a visible pseudomembrane in over 90% of cases, with a mortality rate of roughly one in four hospitalized patients.¹ Before widespread vaccination, diphtheria killed thousands of children each year in industrialized countries. It is now rare where vaccination rates are high but can resurge quickly when coverage drops.

Tetanus is different from the other two diseases in a crucial way: it is not contagious. You get it when spores of Clostridium tetani, found in soil and dust, enter the body through a wound. The bacterium produces a toxin called tetanospasmin, which blocks the release of inhibitory neurotransmitters in the spinal cord and brainstem. Without that chemical braking system, motor neurons fire uncontrollably, causing severe muscle rigidity and violent spasms.² The classic symptom is “lockjaw,” where the jaw muscles clamp shut, but spasms can spread to the respiratory muscles, causing suffocation. Even with modern intensive care, tetanus carries a high fatality rate, and neonatal tetanus remains a killer in parts of the world where mothers are unvaccinated and umbilical cord care is poor.³

Pertussis, commonly called whooping cough, is caused by Bordetella pertussis and is extremely contagious. It produces prolonged coughing fits that can last for weeks or months, sometimes ending with a characteristic “whoop” as the person gasps for air. In young infants, the biggest danger is not the cough itself but the pauses in breathing (apnea), cyanosis (turning blue), and secondary pneumonia. Risk factors for severe pertussis in very young infants include fever, cyanotic episodes, and very high white blood cell counts.⁴ Despite widespread vaccination, pertussis remains a persistent global health challenge.⁵

What “Whole-Cell” Actually Means

The key distinction that defines DTwP is the pertussis component. In a whole-cell pertussis vaccine, the Bordetella pertussis bacteria are grown in culture, killed (usually with chemicals like formaldehyde or glutaraldehyde), and included in the vaccine more or less intact.⁶ This means the immune system gets exposed to the full array of bacterial proteins, lipopolysaccharides, and other surface molecules, not just a few selected pieces. The result is a broad immune response that closely mimics what happens during natural infection.

By contrast, acellular pertussis vaccines (the “aP” in DTaP) contain only a handful of purified pertussis proteins, typically between one and five antigens such as pertussis toxin and filamentous hemagglutinin. This streamlined approach produces fewer side effects but, as researchers have increasingly recognized, generates a narrower immune response. The diphtheria and tetanus components are the same in both vaccines: chemically inactivated toxins (toxoids) that train the immune system to neutralize the poisons these bacteria produce, adsorbed onto an aluminum salt adjuvant to boost the response.

How DTwP and DTaP Compare

The switch from whole-cell to acellular pertussis vaccines in wealthy countries during the 1990s was driven primarily by concerns about side effects. The United States made the transition following global safety worries about whole-cell vaccines.⁷ DTwP commonly causes more local reactions at the injection site (redness, swelling, pain) and more systemic reactions like fever and irritability compared to DTaP.⁸ For parents watching their baby run a fever and cry after a shot, this difference matters.

But there is a tradeoff that took years to become clear. DTwP appears to generate a more robust and longer-lasting immune response against pertussis. In a study comparing the two vaccines in Indonesian children, the whole-cell vaccine produced significantly higher levels of agglutinating antibodies against B. pertussis, while the acellular vaccine produced higher levels of antibodies against specific purified antigens like pertussis toxin.⁹ Those agglutinating antibodies reflect a broader immune recognition of the whole bacterium, which may matter for preventing not just disease but also colonization and spread.

A landmark baboon study demonstrated this point vividly. Animals vaccinated with acellular pertussis vaccine were protected from severe symptoms but were still colonized by the bacteria and readily transmitted the infection to unvaccinated contacts. Animals vaccinated with whole-cell pertussis vaccine cleared the infection more rapidly.¹⁰ This finding has been echoed by immunological studies showing that acellular vaccines skew the immune response in a direction that is less effective at clearing colonization, while whole-cell vaccines and natural infection both promote a type of immune response that does clear the bacteria faster.¹¹

The Pertussis Resurgence Problem

The practical consequence of the DTaP-DTwP difference has played out on a national scale. In the United States, after the full switch from whole-cell to acellular pertussis vaccines by 1997, pertussis cases climbed from about 4,000 in 1992 to over 35,000 in 2024, with major cyclical outbreaks along the way.¹² The vaccine type showed a significant association with case numbers even after adjusting for vaccination coverage, suggesting that the switch itself, not just changes in who gets vaccinated, has contributed to the resurgence.

This does not mean acellular vaccines are useless. They clearly prevent severe disease and death. But the evidence suggests they are less effective at preventing the silent carriage and transmission of B. pertussis in the community. The result is a population where vaccinated teenagers and adults can unknowingly harbor and spread the bacterium, putting vulnerable young infants (who have not yet completed their vaccine series) at risk. To help close that gap, the U.S. introduced a recommendation in 2011 for pregnant women to receive a Tdap booster during each pregnancy, transferring protective antibodies to the baby before birth.¹³

Countries that never switched away from whole-cell pertussis vaccines have generally not experienced the same kind of resurgence. This has prompted serious scientific discussion about whether the move to acellular vaccines, while solving one problem (reactogenicity), created another (waning herd protection).

The Safety Controversy That Drove the Switch

The fears about DTwP that prompted the transition to acellular vaccines deserve careful examination, because they shaped global vaccine policy for decades. In the 1970s and 1980s, case reports and case series described children developing encephalopathy (brain inflammation) or seizures shortly after receiving DTP (whole-cell) vaccine. Media coverage amplified these reports into a widespread belief that the vaccine caused brain damage.

The scientific evidence, however, does not support that belief. A thorough review of the literature found no consistent evidence for a specific “DTP encephalopathy” syndrome and concluded that neurologic events after immunization were most likely coincidental, occurring in children who were at the age when idiopathic neurologic conditions naturally emerge, regardless of vaccination.¹⁴ There is an increased risk of a febrile seizure after DTP vaccination, but no evidence that these seizures produce lasting brain injury or lead to epilepsy. The widespread impression of brain damage was based heavily on case series, which can generate hypotheses but cannot prove causation, and on analogy to other vaccines (like early rabies vaccines) that genuinely did cause neurologic complications.¹⁵

The one major case-control study that found a rare association between DTP and acute neurologic illness (the British National Childhood Encephalopathy Study, or NCES) did not demonstrate that the vaccine caused permanent brain damage, and its finding was never replicated by another case-control study. Nonetheless, the political and public pressure was enough to drive the development and adoption of acellular alternatives. In hindsight, the situation is a cautionary example of how anecdotal evidence and media amplification can reshape policy beyond what the science strictly supports.

DTwP in Combination Vaccines

In many countries, DTwP is not given on its own anymore. It is bundled into combination vaccines that reduce the total number of injections a child needs. The most common combination is a pentavalent (five-in-one) vaccine that adds hepatitis B and Haemophilus influenzae type b (Hib) protection to the DTwP base. These pentavalent vaccines have been a cornerstone of global immunization programs, supported by organizations like Gavi and WHO.

Clinical trials of pentavalent DTwP-HepB-Hib vaccines have shown strong immune responses. In one large study of Indian infants receiving doses at 6, 10, and 14 weeks of age, the proportions achieving protective antibody levels after the third dose were 99% for diphtheria, 100% for tetanus, 98% for hepatitis B, 100% for short-term Hib protection, and 99% for pertussis.¹⁶ No vaccine-related serious adverse events were reported in that trial. Comparable results have been seen with pentavalent vaccines from other manufacturers, with pain, redness, and swelling at the injection site being the most common local reactions and fever and irritability the most common systemic ones.⁸

One nuance worth noting: the choice of combination vaccine can affect the immune response to individual components. A study following children to age seven found that those who received a DTwP-based pentavalent vaccine had lower long-term hepatitis B antibody levels compared to children who received a hexavalent (DTaP-based) vaccine, despite both containing the same amount of hepatitis B antigen.¹⁷ The reasons for this are not entirely clear but may relate to interactions between the whole-cell pertussis component and the other antigens in the formulation. This does not necessarily mean protection is lost, since immune memory can persist even when measurable antibodies decline, but it is an area researchers continue to watch.

Why DTwP Persists Where DTaP Is Available

Cost is a major factor. DTwP-based vaccines are substantially cheaper to manufacture than DTaP-based ones. The whole-cell pertussis component requires growing and killing bacteria rather than the more complex process of purifying individual proteins. For countries vaccinating millions of children with limited budgets, this price difference is not trivial. A 1997 economic analysis in the U.S. found that DTaP and DTwP produced nearly identical net savings from a societal perspective, but acknowledged that any small cost increase from DTaP might be offset by the value of reduced adverse events and increased public confidence in vaccination.¹⁸ In wealthy countries, that tradeoff tipped toward DTaP. In resource-limited settings, DTwP remains the pragmatic choice, and the evidence suggesting it may actually be better at preventing transmission adds a scientific rationale on top of the economic one.

There is also an ongoing debate about whether DTwP has non-specific effects on mortality, meaning effects beyond the three diseases it targets. A WHO-commissioned review estimated the relative risk of all-cause mortality after DTwP vaccination at about 1.38, but with wide confidence intervals that crossed 1.0, meaning the finding was not statistically significant and could easily reflect bias or confounding rather than a real effect.¹⁹ A meta-regression found that study location, analytical approach, and risk of misclassification bias were significantly associated with higher estimates, suggesting that methodological differences between studies explained much of the variation. WHO has not changed its recommendations based on these findings, and the consensus remains that DTwP’s benefits clearly outweigh its risks.

Rare Reactions and What to Watch For

Beyond the common side effects of fever, fussiness, and injection-site soreness, there are a few less common reactions that parents and clinicians should know about. One is the hypotonic-hyporesponsive episode (HHE), in which a baby becomes suddenly pale, floppy, and less responsive, typically within hours of vaccination. While alarming to witness, HHE resolves completely in all reported cases with no long-term effects. Current guidance no longer considers HHE a reason to withhold further doses of pertussis vaccine, though each case should be evaluated individually by a pediatrician.²⁰

Febrile seizures after DTwP are also more common than after DTaP, occurring in roughly the range of one per several thousand doses. These are brief, self-limited, and do not cause brain damage or increase the risk of epilepsy, as confirmed by multiple studies. The higher rate of these reactions was a genuine disadvantage of whole-cell vaccines and one of the legitimate reasons the switch to acellular vaccines made sense in settings where the cost difference was manageable.

How DTwP Changed the Trajectory of Three Diseases

Before DTwP vaccines came into routine use, all three target diseases were common childhood killers. In the United States, the average rate of reported pertussis cases dropped from 157 per 100,000 in the pre-vaccine era to less than 1 per 100,000 by the 1970s.²¹ Diphtheria, once one of the leading causes of childhood death, became so rare in vaccinated populations that many physicians in high-income countries have never seen a case. Tetanus cases plummeted wherever vaccination and wound hygiene improved together.

The global story is more uneven. In countries with high vaccination coverage, all three diseases are mostly controlled. In countries with fragile health systems or recent disruptions to immunization programs, outbreaks still occur. The Nigerian diphtheria outbreak of 2023-2024, in which nearly two-thirds of affected children were unvaccinated, is a stark recent example of what happens when coverage lapses.¹ These are not diseases of the past. They are diseases held at bay by consistent vaccination, and they will return whenever that barrier weakens.

How Pertussis Adapts

One dimension of the pertussis problem that goes beyond vaccine type is the bacterium itself. Bordetella pertussis is not a static target. Research has shown that conditions in the human nasal passages reprogram the bacterium into a state of heightened virulence, helping it attach to and remodel nasal epithelial cells more efficiently.²² This kind of environmental adaptation means that the bacterium we study in the lab is not identical to the one that infects people, which has implications for how we design vaccines and interpret laboratory studies of immune protection.

There is also evidence that B. pertussis strains have been evolving in response to vaccination pressure, with shifts in the pertussis toxin gene and other surface antigens. Whether these changes are making current vaccines less effective is debated, but it adds another layer to the puzzle of why pertussis has not been eliminated the way some hoped it would be. This is one reason why next-generation pertussis vaccines, potentially combining the broad immune stimulation of whole-cell approaches with the lower reactogenicity of acellular ones, are an active area of research. The field is essentially trying to get the best of both worlds: a vaccine that is well-tolerated enough for universal acceptance but immunologically potent enough to block not just disease but transmission.